Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17256784 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | December 2020 | January 2024 | Allow | 36 | 2 | 1 | Yes | No |
| 17046690 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | October 2020 | December 2023 | Allow | 38 | 3 | 1 | Yes | No |
| 16948893 | SOLID-STATE FORMS OF ABEMACICLIB, THEIR USE AND PREPARATION | October 2020 | February 2023 | Abandon | 28 | 0 | 1 | No | No |
| 16733571 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | January 2020 | March 2024 | Abandon | 51 | 5 | 1 | Yes | Yes |
| 16704402 | TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS | December 2019 | October 2020 | Allow | 10 | 1 | 1 | Yes | No |
| 16383307 | DEUTERATED COMPOUNDS AND MEDICAL USES THEREOF | April 2019 | January 2020 | Allow | 9 | 1 | 0 | No | No |
| 16377005 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | April 2019 | August 2019 | Allow | 4 | 0 | 0 | No | No |
| 16245131 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | January 2019 | August 2019 | Allow | 7 | 0 | 1 | No | No |
| 16239578 | Quinazoline Compounds | January 2019 | September 2019 | Allow | 8 | 0 | 1 | No | No |
| 16228324 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | December 2018 | September 2019 | Allow | 9 | 1 | 0 | Yes | No |
| 16310221 | PYRROLOPYRIMIDINE COMPRISING CYCLOPENTYL SUBSTITUENT | December 2018 | December 2019 | Allow | 12 | 1 | 0 | No | No |
| 16190632 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | November 2018 | March 2020 | Abandon | 16 | 2 | 0 | No | No |
| 16184009 | NEW CRYSTAL FORMS OF PALBOCICLIB, AND PREPARATION METHOD AND USE THEREFOR | November 2018 | September 2019 | Allow | 10 | 1 | 1 | Yes | No |
| 16179174 | PROTEIN KINASE INHIBITORS | November 2018 | November 2019 | Allow | 12 | 1 | 0 | No | No |
| 16098338 | TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS | November 2018 | September 2019 | Allow | 10 | 0 | 0 | Yes | No |
| 16176501 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | October 2018 | June 2019 | Allow | 8 | 0 | 0 | No | No |
| 16174350 | ARTIFICIAL SELF-SUFFICIENT CYTOCHROME P450S | October 2018 | September 2019 | Allow | 11 | 0 | 0 | No | No |
| 16170137 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF {1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]AZETIDIN-3-YL}ACETONITRILE | October 2018 | November 2019 | Abandon | 13 | 0 | 1 | No | No |
| 16087318 | SALT FORM OF DPPIV INHIBITOR AND PREPARATION METHOD THEREOF | October 2018 | October 2019 | Allow | 13 | 1 | 0 | No | No |
| 16155905 | METHOD OF PREPARATION OF FLORASULAM | October 2018 | November 2019 | Abandon | 13 | 1 | 0 | No | No |
| 16151766 | DIKETOPIPERAZINE SALTS FOR DRUG DELIVERY AND RELATED METHODS | October 2018 | October 2019 | Allow | 13 | 2 | 0 | No | No |
| 16150787 | ADSORPTION OF FLUORINATED ANESTHETICS WITHIN THE PORES OF MOLECULAR CRYSTALS | October 2018 | June 2019 | Allow | 8 | 1 | 0 | No | No |
| 16088695 | SILICON INCORPORATED QUINOLINES WITH ANTI-MALARIAL AND ANTI-TOXOPLASMOSIS ACTIVITY | September 2018 | September 2019 | Allow | 12 | 1 | 0 | No | No |
| 16087861 | SUBSTITUTED-INDOLE-COMPOUNDS AS ESTROGEN RECEPTOR DOWN-REGULATORS | September 2018 | August 2019 | Allow | 11 | 1 | 0 | No | No |
| 16085829 | PROCESS FOR PREPARING SUBSTITUTED 9,10-DIOXO-9,10-DIHYDROANTHRECENES AND 6H-ANTHRA[1,9-CD]ISOXAZOL-6-ONES | September 2018 | June 2019 | Allow | 9 | 0 | 1 | No | No |
| 16132411 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | September 2018 | August 2019 | Allow | 11 | 1 | 1 | Yes | No |
| 16083128 | SYNTHESIS OF 2'-FLUORO-6'-METHYLENE-CARBOCYCLIC ADENOSINE (FMCA) AND 2'-FLUORO-6'-METHYLENE-CARBOCYCLIC GUANOSINE (FMCG) | September 2018 | August 2019 | Allow | 11 | 1 | 1 | No | No |
| 16082437 | METHODS AND COMPOSITIONS FOR TREATMENT OF ZIKA VIRUS INFECTION | September 2018 | August 2019 | Allow | 11 | 1 | 0 | Yes | No |
| 16116425 | SALTS AND SOLID FORM OF A BTK INHIBITOR | August 2018 | July 2019 | Allow | 10 | 1 | 0 | Yes | No |
| 16078715 | PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES | August 2018 | March 2019 | Allow | 7 | 0 | 0 | Yes | No |
| 16106180 | NOVEL PHOSPHORUS COMPOUNDS, SYNTHESIS METHOD THEREOF, AND POLYCARBONATE RESIN COMPOSITION INCLUDING THEM | August 2018 | October 2019 | Allow | 14 | 0 | 1 | No | No |
| 16107103 | SYNTHESIS OF CYCLOCREATINE AND ANALOGS THEREOF | August 2018 | May 2019 | Allow | 9 | 0 | 1 | No | No |
| 16078155 | GLYCOSIDASE INHIBITORS | August 2018 | October 2019 | Allow | 14 | 1 | 1 | No | No |
| 15999635 | Photocleavable Chemical Inducers of Dimerization (CID) and Methods of Use | August 2018 | February 2020 | Abandon | 18 | 0 | 1 | No | No |
| 15998769 | Fungicidal pyridazinones | August 2018 | November 2019 | Abandon | 15 | 0 | 1 | No | No |
| 16073809 | PROCESS FOR THE PREPARATION OF IBRUTINIB | July 2018 | August 2019 | Allow | 12 | 1 | 0 | No | No |
| 16048051 | Allosteric Modulators of the Mu Opioid Receptor | July 2018 | November 2019 | Allow | 16 | 1 | 1 | Yes | No |
| 16031357 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | July 2018 | August 2019 | Allow | 13 | 2 | 0 | No | No |
| 16022578 | PPAR AGONISTS AND METHODS OF USE THEREOF | June 2018 | September 2019 | Allow | 15 | 2 | 0 | No | No |
| 16066425 | Crystalline Form Of Ticagrelor | June 2018 | January 2019 | Allow | 6 | 0 | 0 | No | No |
| 16014678 | INTERMEDIATE COMPOUNDS FOR PREPARATION OF PRAZIQUANTEL AND PROCESSES FOR PREPARING THE INTERMEDIATE COMPOUNDS | June 2018 | August 2019 | Allow | 14 | 1 | 1 | No | No |
| 16008421 | PYRAZOLOPYRIMIDINE COMPOUNDS | June 2018 | December 2019 | Abandon | 18 | 2 | 0 | Yes | No |
| 16004062 | PURINONE COMPOUNDS AS KINASE INHIBITORS | June 2018 | September 2019 | Abandon | 16 | 1 | 0 | No | No |
| 16003374 | SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING BIOPTERIN DERIVATIVES AND USES OF SUCH COMPOSITIONS | June 2018 | July 2019 | Allow | 13 | 2 | 0 | No | No |
| 16000338 | NOVEL CHROMONE OXIME DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | June 2018 | May 2019 | Allow | 12 | 1 | 0 | No | No |
| 15988920 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | May 2018 | September 2019 | Allow | 16 | 2 | 0 | No | No |
| 15975462 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | May 2018 | April 2019 | Allow | 11 | 1 | 0 | No | No |
| 15970544 | DTPA PRODRUGS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | May 2018 | June 2019 | Abandon | 13 | 0 | 1 | No | No |
| 15955523 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | April 2018 | September 2019 | Allow | 17 | 2 | 1 | No | No |
| 15950606 | FORMS OF A PI3K DELTA SELECTIVE INHIBITOR FOR USE IN PHARMACEUTICAL FORMULATIONS | April 2018 | May 2019 | Allow | 13 | 0 | 1 | No | No |
| 15945324 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | April 2018 | August 2019 | Allow | 16 | 1 | 1 | No | No |
| 15939953 | METHOD OF TREATING INSOMNIA | March 2018 | January 2019 | Allow | 9 | 0 | 0 | No | No |
| 15938292 | POTASSIUM CHANNEL MODULATORS | March 2018 | April 2019 | Allow | 13 | 1 | 1 | Yes | No |
| 15936868 | Method for preparing acrolein cyanohydrins | March 2018 | November 2018 | Allow | 8 | 0 | 1 | No | No |
| 15924020 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | March 2018 | September 2019 | Abandon | 18 | 1 | 1 | No | No |
| 15922980 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | March 2018 | January 2019 | Allow | 10 | 1 | 1 | Yes | No |
| 15918852 | CDK INHIBITORS | March 2018 | September 2018 | Allow | 6 | 1 | 0 | No | No |
| 15918834 | CDK Inhibitors | March 2018 | September 2018 | Allow | 6 | 1 | 0 | No | No |
| 15918877 | CDK INHIBITORS | March 2018 | September 2018 | Allow | 6 | 1 | 0 | No | No |
| 15916986 | FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES | March 2018 | May 2019 | Abandon | 14 | 0 | 1 | No | No |
| 15909200 | THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | March 2018 | March 2019 | Allow | 13 | 1 | 0 | No | No |
| 15907007 | ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | February 2018 | March 2019 | Allow | 13 | 1 | 0 | No | No |
| 15753567 | UREA DERIVATIVE AND USE THEREFOR | February 2018 | December 2018 | Allow | 10 | 1 | 0 | No | No |
| 15752635 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | February 2018 | April 2019 | Allow | 14 | 1 | 0 | No | No |
| 15893779 | THIENO- AND PYRROLOPYRIMIDINE ANALOGUES AS ANTICANCER AGENTS AND METHODS OF USE THEREOF | February 2018 | October 2019 | Allow | 20 | 3 | 0 | No | No |
| 15887744 | CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR | February 2018 | October 2018 | Abandon | 9 | 1 | 0 | No | No |
| 15887712 | CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR | February 2018 | November 2018 | Abandon | 9 | 1 | 0 | No | No |
| 15886426 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | February 2018 | May 2019 | Abandon | 16 | 0 | 1 | No | No |
| 15885435 | TREATMENT OF KIDNEY DISEASES ASSOCIATED WITH ELEVATED AVP | January 2018 | November 2019 | Allow | 22 | 1 | 1 | No | No |
| 15877910 | POTASSIUM CHANNEL MODULATORS | January 2018 | March 2018 | Allow | 2 | 0 | 0 | No | No |
| 15874163 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | January 2018 | March 2019 | Allow | 14 | 1 | 0 | No | No |
| 15873450 | DIHYDROPYRIMIDINONE DERIVATIVES | January 2018 | June 2018 | Allow | 5 | 1 | 0 | Yes | No |
| 15872769 | CRYSTALLINE FORM OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROGEN SULFATE | January 2018 | October 2018 | Allow | 9 | 1 | 0 | No | No |
| 15871333 | ORGANIC LIGHT-EMITTING DEVICE | January 2018 | February 2019 | Allow | 13 | 1 | 0 | No | No |
| 15864499 | COMPOUNDS THAT INHIBIT MPS1 KINASE | January 2018 | July 2019 | Allow | 18 | 2 | 0 | No | No |
| 15741722 | A process for the preparation of Lorcaserin Hydrochloride | January 2018 | January 2019 | Allow | 13 | 1 | 0 | No | No |
| 15730664 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | January 2018 | September 2018 | Allow | 11 | 0 | 0 | No | No |
| 15861287 | N2-PHENYL-PYRIDO[3,4- D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | January 2018 | May 2019 | Allow | 16 | 1 | 1 | No | No |
| 15853368 | IBRUTINIB SOLID FORMS AND PRODUCTION PROCESS THEREFOR | December 2017 | December 2018 | Allow | 12 | 0 | 1 | No | No |
| 15850720 | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | December 2017 | October 2019 | Allow | 22 | 2 | 1 | No | No |
| 15848075 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | December 2017 | May 2019 | Allow | 17 | 1 | 1 | No | No |
| 15839332 | PROTEIN KINASE INHIBITORS | December 2017 | October 2018 | Allow | 10 | 2 | 1 | Yes | No |
| 15836763 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | December 2017 | June 2018 | Allow | 6 | 0 | 1 | No | No |
| 15579612 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF {1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]AZETIDIN-3-YL}ACETONITRILE | December 2017 | March 2018 | Allow | 3 | 0 | 0 | No | No |
| 15830178 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | December 2017 | February 2019 | Allow | 15 | 1 | 0 | No | No |
| 15829028 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | December 2017 | April 2019 | Abandon | 16 | 1 | 0 | No | No |
| 15578775 | BTK INHIBITORS | December 2017 | April 2019 | Abandon | 16 | 1 | 0 | No | No |
| 15827471 | Crystalline Forms of Ibrutinib | November 2017 | September 2018 | Allow | 9 | 0 | 1 | No | No |
| 15826898 | TETRACYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | November 2017 | March 2019 | Allow | 16 | 1 | 1 | No | No |
| 15827985 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | November 2017 | May 2019 | Allow | 18 | 2 | 1 | No | No |
| 15818035 | Novel Heterocyclic Derivatives as Modulators of Kinase Activity | November 2017 | December 2018 | Allow | 13 | 1 | 0 | No | No |
| 15817973 | DE NOVO SYNTHESIS OF BACTERIOCHLORINS | November 2017 | November 2018 | Allow | 12 | 1 | 0 | Yes | No |
| 15817487 | PROCESS FOR THE MANUFACTURE OF IXABEPILONE | November 2017 | June 2019 | Allow | 19 | 2 | 0 | No | No |
| 15815809 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | November 2017 | December 2018 | Allow | 13 | 1 | 1 | No | No |
| 15803379 | MODULATION OF N-ACYLETHANOLAMINE-HYDROLYSING ACID AMIDASE (NAAA) FOR DISEASE TREATMENT | November 2017 | November 2018 | Allow | 12 | 1 | 0 | No | No |
| 15799315 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | October 2017 | December 2018 | Allow | 14 | 1 | 1 | No | No |
| 15799661 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | October 2017 | June 2018 | Allow | 8 | 1 | 0 | No | No |
| 15797568 | METHOD FOR PRODUCING AROMATIC COMPOUND | October 2017 | January 2019 | Allow | 15 | 2 | 0 | Yes | No |
| 15566914 | WHITE LIGHT EMITTING ZIRCONIUM-BASED MOFS | October 2017 | October 2019 | Abandon | 24 | 2 | 1 | No | No |
| 15783373 | PYRIDOPYRIMIDINONES AND METHODS OF USE THEREOF | October 2017 | December 2018 | Allow | 14 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MURRAY, JEFFREY H.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 43.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner MURRAY, JEFFREY H works in Art Unit 1624 and has examined 1,125 patent applications in our dataset. With an allowance rate of 70.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 21 months.
Examiner MURRAY, JEFFREY H's allowance rate of 70.8% places them in the 35% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by MURRAY, JEFFREY H receive 1.20 office actions before reaching final disposition. This places the examiner in the 13% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by MURRAY, JEFFREY H is 21 months. This places the examiner in the 89% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +30.7% benefit to allowance rate for applications examined by MURRAY, JEFFREY H. This interview benefit is in the 78% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 39.5% of applications are subsequently allowed. This success rate is in the 90% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 74.4% of cases where such amendments are filed. This entry rate is in the 94% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 52.3% are granted (fully or in part). This grant rate is in the 50% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 3.8% of allowed cases (in the 83% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.8% of allowed cases (in the 82% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.